| Pharmaceutical Information |
| Drug Name |
Lixisenatide |
| Drug ID |
BADD_D01306 |
| Description |
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes mellitus (T2DM). It is sold under the brand name Adlyxin by Sanofi-Aventis. Adlyxin recieved FDA approval July 28, 2016 [L763]. |
| Indications and Usage |
For use as an antihyperglycemic agent in the treatment of T2DM [FDA Label]. |
| Marketing Status |
Prescription |
| ATC Code |
A10BJ03 |
| DrugBank ID |
DB09265
|
| KEGG ID |
D09729
|
| MeSH ID |
C479460
|
| PubChem ID |
90472060
|
| TTD Drug ID |
D05MKA
|
| NDC Product Code |
0024-5745; 0024-5747 |
| Synonyms |
lixisenatide | DES-38-proline-exendine-4 (Heloderma suspectum)-(1-39)-peptidylpenta-l-lysyl-l-lysinamide | Adlyxin | AQVE-10010 | ZP10A peptide | ZP 10 | ZP-10 | Lyxumia | AVE 010 | AVE-010 | AVE 0010 | AVE0010 | AVE-0010 |
|
| Chemical Information |
| Molecular Formula |
C215H347N61O65S |
| CAS Registry Number |
320367-13-3 |
| SMILES |
CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN
)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(
C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C
(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(CC(
C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O
)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C
(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(C(
C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC8=CNC=N8)N |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
